Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1531 | 7464 | 53.1 | 92% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
262 | 3 | AUTOPHAGY//RESVERATROL//HISTONE DEACETYLASE INHIBITOR | 44558 |
1531 | 2 | HISTONE DEACETYLASE INHIBITOR//HISTONE DEACETYLASE//HDAC INHIBITOR | 7464 |
185 | 1 | HISTONE DEACETYLASE INHIBITOR//HISTONE DEACETYLASE//HDAC INHIBITOR | 4003 |
6500 | 1 | EPIGENETICS//DNA METHYLATION//HISTONE ACETYLATION | 1477 |
16802 | 1 | MEF2C//MEF2//MEF2D | 635 |
17566 | 1 | TRAUMA EMERGENCY SURG SURG CRIT CAREMASSAC//HISTONE DEACETYLASE//SURG TRAUMA EMERGENCY SURG SURG CRIT C | 593 |
18909 | 1 | PROTEIN KINASE D//PROTEIN KINASE D PKD//PROTEIN KINASE C MU | 531 |
27625 | 1 | METABOLIC MEMORY//IL RISK ASSESSMENT INTERVENT STUDIES//HYPERGLYCEMIC MEMORY | 225 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | HISTONE DEACETYLASE INHIBITOR | authKW | 1693713 | 10% | 54% | 766 |
2 | HISTONE DEACETYLASE | authKW | 1376463 | 10% | 44% | 766 |
3 | HDAC INHIBITOR | authKW | 893419 | 6% | 52% | 420 |
4 | HDAC | authKW | 486821 | 4% | 38% | 312 |
5 | VORINOSTAT | authKW | 290365 | 2% | 53% | 133 |
6 | SAHA | authKW | 285632 | 2% | 57% | 122 |
7 | EPIGENETICS | authKW | 240480 | 11% | 7% | 799 |
8 | TRICHOSTATIN A | authKW | 237210 | 2% | 32% | 184 |
9 | SUBEROYLANILIDE HYDROXAMIC ACID | authKW | 186861 | 1% | 57% | 80 |
10 | PANOBINOSTAT | authKW | 164361 | 1% | 59% | 68 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 12285 | 22% | 0% | 1669 |
2 | Chemistry, Medicinal | 6333 | 9% | 0% | 692 |
3 | Cell Biology | 4787 | 15% | 0% | 1091 |
4 | Biochemistry & Molecular Biology | 4249 | 23% | 0% | 1734 |
5 | Neurosciences | 3181 | 14% | 0% | 1064 |
6 | Pharmacology & Pharmacy | 1803 | 12% | 0% | 860 |
7 | Genetics & Heredity | 848 | 6% | 0% | 438 |
8 | Hematology | 845 | 4% | 0% | 303 |
9 | Psychiatry | 738 | 5% | 0% | 351 |
10 | Medicine, Research & Experimental | 661 | 5% | 0% | 351 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | EPIGENET HUMAN HLTH DIS | 40801 | 0% | 37% | 27 |
2 | UNIT SIGNAL TRANSDUCT GASTROINTESTINAL CANC | 30917 | 0% | 69% | 11 |
3 | SACKLER PROGRAM EPIGENET PSYCHOBIOL | 23634 | 0% | 32% | 18 |
4 | IL RISK ASSESSMENT INTERVENT STUDIES | 20925 | 0% | 39% | 13 |
5 | DIPARTIMENTO PATOL GEN | 20472 | 0% | 16% | 32 |
6 | ROGER WILLIAM MED | 20125 | 0% | 62% | 8 |
7 | EPIGEN PROFILING IL | 18576 | 0% | 45% | 10 |
8 | EVELYN F MCKNIGHT BRAIN | 18270 | 1% | 12% | 38 |
9 | BRUDNICK NEUROPSYCHIAT | 18243 | 0% | 17% | 27 |
10 | MOL GENET PREPARAT MOL BIOL | 17026 | 0% | 42% | 10 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | EPIGENOMICS | 17056 | 1% | 10% | 44 |
2 | MOLECULAR CANCER THERAPEUTICS | 6298 | 1% | 2% | 80 |
3 | CLINICAL EPIGENETICS | 4833 | 0% | 5% | 22 |
4 | INFLAMMOPHARMACOLOGY | 4245 | 0% | 9% | 12 |
5 | CIBA FOUNDATION SYMPOSIA | 4127 | 1% | 2% | 53 |
6 | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 3793 | 2% | 1% | 158 |
7 | CLINICAL CANCER RESEARCH | 3768 | 2% | 1% | 120 |
8 | JOURNAL OF MEDICINAL CHEMISTRY | 3148 | 2% | 1% | 133 |
9 | TRANSLATIONAL PSYCHIATRY | 3139 | 0% | 3% | 27 |
10 | INVESTIGATIONAL NEW DRUGS | 2619 | 1% | 2% | 41 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | HISTONE DEACETYLASE INHIBITOR | 1693713 | 10% | 54% | 766 | Search HISTONE+DEACETYLASE+INHIBITOR | Search HISTONE+DEACETYLASE+INHIBITOR |
2 | HISTONE DEACETYLASE | 1376463 | 10% | 44% | 766 | Search HISTONE+DEACETYLASE | Search HISTONE+DEACETYLASE |
3 | HDAC INHIBITOR | 893419 | 6% | 52% | 420 | Search HDAC+INHIBITOR | Search HDAC+INHIBITOR |
4 | HDAC | 486821 | 4% | 38% | 312 | Search HDAC | Search HDAC |
5 | VORINOSTAT | 290365 | 2% | 53% | 133 | Search VORINOSTAT | Search VORINOSTAT |
6 | SAHA | 285632 | 2% | 57% | 122 | Search SAHA | Search SAHA |
7 | EPIGENETICS | 240480 | 11% | 7% | 799 | Search EPIGENETICS | Search EPIGENETICS |
8 | TRICHOSTATIN A | 237210 | 2% | 32% | 184 | Search TRICHOSTATIN+A | Search TRICHOSTATIN+A |
9 | SUBEROYLANILIDE HYDROXAMIC ACID | 186861 | 1% | 57% | 80 | Search SUBEROYLANILIDE+HYDROXAMIC+ACID | Search SUBEROYLANILIDE+HYDROXAMIC+ACID |
10 | PANOBINOSTAT | 164361 | 1% | 59% | 68 | Search PANOBINOSTAT | Search PANOBINOSTAT |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | BOLDEN, JE , PEART, MJ , JOHNSTONE, RW , (2006) ANTICANCER ACTIVITIES OF HISTONE DEACETYLASE INHIBITORS.NATURE REVIEWS DRUG DISCOVERY. VOL. 5. ISSUE 9. P. 769-784 | 140 | 71% | 1602 |
2 | FALKENBERG, KJ , JOHNSTONE, RW , (2014) HISTONE DEACETYLASES AND THEIR INHIBITORS IN CANCER, NEUROLOGICAL DISEASES AND IMMUNE DISORDERS.NATURE REVIEWS DRUG DISCOVERY. VOL. 13. ISSUE 9. P. 673 -691 | 152 | 57% | 254 |
3 | MOTTAMAL, M , ZHENG, SL , HUANG, TL , WANG, GD , (2015) HISTONE DEACETYLASE INHIBITORS IN CLINICAL STUDIES AS TEMPLATES FOR NEW ANTICANCER AGENTS.MOLECULES. VOL. 20. ISSUE 3. P. 3898 -3941 | 135 | 71% | 77 |
4 | WEST, AC , JOHNSTONE, RW , (2014) NEW AND EMERGING HDAC INHIBITORS FOR CANCER TREATMENT.JOURNAL OF CLINICAL INVESTIGATION. VOL. 124. ISSUE 1. P. 30-39 | 96 | 78% | 256 |
5 | KOLLAR, J , FRECER, V , (2015) SELECTIVE INHIBITORS OF ZINC-DEPENDENT HISTONE DEACETYLASES. THERAPEUTIC TARGETS RELEVANT TO CANCER.CURRENT PHARMACEUTICAL DESIGN. VOL. 21. ISSUE 11. P. 1472 -1502 | 209 | 80% | 0 |
6 | THALER, F , MERCURIO, C , (2014) TOWARDS SELECTIVE INHIBITION OF HISTONE DEACETYLASE ISOFORMS: WHAT HAS BEEN ACHIEVED, WHERE WE ARE AND WHAT WILL BE NEXT.CHEMMEDCHEM. VOL. 9. ISSUE 3. P. 523-536 | 155 | 89% | 27 |
7 | MANAL, M , CHANDRASEKAR, MJN , PRIYA, JG , NANJAN, MJ , (2016) INHIBITORS OF HISTONE DEACETYLASE AS ANTITUMOR AGENTS: A CRITICAL REVIEW.BIOORGANIC CHEMISTRY. VOL. 67. ISSUE . P. 18 -42 | 142 | 78% | 6 |
8 | LEE, JH , CHOY, ML , MARKS, PA , (2012) MECHANISMS OF RESISTANCE TO HISTONE DEACETYLASE INHIBITORS.HISTONE DEACETYLASE INHIBITORS AS CANCER THERAPEUTICS. VOL. 116. ISSUE . P. 39-86 | 186 | 78% | 26 |
9 | WITT, O , DEUBZER, HE , MILDE, T , OEHME, I , (2009) HDAC FAMILY: WHAT ARE THE CANCER RELEVANT TARGETS?.CANCER LETTERS. VOL. 277. ISSUE 1. P. 8-21 | 100 | 87% | 411 |
10 | ROCHE, J , BERTRAND, P , (2016) INSIDE HDACS WITH MORE SELECTIVE HDAC INHIBITORS.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. VOL. 121. ISSUE . P. 451 -483 | 141 | 76% | 3 |
Classes with closest relation at Level 2 |
Rank | Class id | link |
---|---|---|
1 | 2649 | SIRT1//SIRTUINS//SIRT3 |
2 | 382 | DNA METHYLATION//EPIGENETICS//METHYLATION |
3 | 343 | EZH2//CHROMATIN//POLYCOMB |
4 | 3175 | ID 1//NRSF//ID1 |
5 | 3037 | KLF4//KRUPPEL LIKE FACTOR//GADD45 |
6 | 1843 | ACUTE PROMYELOCYTIC LEUKEMIA//ARSENIC TRIOXIDE//SUMO |
7 | 3321 | BLEOMYCIN//MIGRASTATIN//BLEOMYCIN HYDROLASE |
8 | 2158 | NF KAPPA B//I KAPPA B//IKK |
9 | 2654 | NURR1//NUR77//PGC 1 ALPHA |
10 | 3833 | CITED2//BRANCHIO OCULO FACIAL SYNDROME//AP 2 ALPHA |